I am a medical oncologist with a special expertise in developing new chemotherapy regimens for colorectal cancer. During my 30 years at Memorial Sloan Kettering, I conducted some of the first studies using drugs such as irinotecan and oxaliplatin, which are now widely used in patients with colorectal cancer. I also was the lead investigator of a large, multi-institutional study that helped in the Food and Drug Administration’s approval of oxaliplatin for colorectal cancer treatment in the U.S. My research has involved improving the outcome for patients with liver metastases using regional chemotherapy. Regional chemotherapy involves administering drugs into an artery that feeds tumors in the liver. This can be done using an internally implanted pump. The effectiveness of regional chemotherapy given in combination with systemic chemotherapy has led to its use in patients with surgically resected (removed) liver metastases. This combination has decreased the recurrence of disease after liver resection. New studies using this therapy have allowed patients with extensive liver disease who are not eligible for resection to achieve an excellent response, which then allows resection. We have also used this treatment for patients with primary liver cancer.
In addition to my clinical and research responsibilities at Memorial Sloan Kettering, I am a professor of medicine at Weill Cornell Medical College. I am also active in oncology issues on a national level. In 1990, I served as a member of the Oncology Drug Advisory Committee, and I have held various positions at the American Society of Clinical Oncology (ASCO). I was one of ASCO’s directors from 1990 to 1993; chairperson of the Membership Committee from 1986 to 1989; chairperson of the Special Awards Committee from 1991to 1995; a member of the ASCO Grant Selection Committee from 2003 to 2004; and a member of the CEA Tumor Marker Panel. In addition, I was principal investigator of a national CALGB protocol evaluating regional liver therapy versus systemic therapy in patients whose disease had spread from the colon to the liver. The study demonstrated a significant increase in survival with regional therapy. I am also a scientific reviewer for many journals and on the editorial board of three journals.
- Clinical Expertise: Colorectal Cancer; Pseudomyxoma Peritonei; Islet Cell Cancer; Thymoma
- Languages Spoken: English
- Education: MD, University of Medicine and Dentistry of New Jersey
- Residencies: St. Luke's Hospital (New York)
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Nancy E. Kemeny
Clinical Trials Co-Investigated by Nancy E. Kemeny
- A Phase I Study of Hepatic Arterial Infusion with Floxuridine, Dexamethasone, and Gemcitabine after Surgery for Liver Cholangiocarcinoma
- A Phase II Study of Hepatic Arterial Infusion with Floxuridine and Dexamethasone plus Systemic Gemcitabine and Oxaliplatin in Patients with Inoperable Intrahepatic Cholangiocarcinoma
- A Study Assessing Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more